P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls

Background Over 41,000 people are diagnosed with lung cancer annually in the UK with only 8% of men, and 9% of women surviving at least 5 years after diagnosis. Antibodies against the endothelial cell protein endoglin are proving promising in early clinical trials [1]. Many individuals with heredita...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 2013-12, Vol.68 (Suppl 3), p.A78-A79
Main Authors: Hosman, AE, Devlin, HL, Silva, BM, Elphick, AH, Shovlin, CL
Format: Article
Language:English
Subjects:
Lung cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A79
container_issue Suppl 3
container_start_page A78
container_title Thorax
container_volume 68
creator Hosman, AE
Devlin, HL
Silva, BM
Elphick, AH
Shovlin, CL
description Background Over 41,000 people are diagnosed with lung cancer annually in the UK with only 8% of men, and 9% of women surviving at least 5 years after diagnosis. Antibodies against the endothelial cell protein endoglin are proving promising in early clinical trials [1]. Many individuals with hereditary haemorrhagic telangiectasia (HHT) have inherited endoglin mutations. This autosomal dominant trait affects approximately 1 in 5,000 people, causing multi-systemic vascular lesions. We hypothesised that lung cancer rates may differ in individuals with HHT. Methods To provide sufficient power to compare lung cancer rates in HHT patients and controls, we developed a questionnaire capturing data on multiple relatives per respondent, powered to detect differences in lung cancer rates. Blinded to cancer responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subject, unknown, or control. Logistic and quadratic regression were used to calculate crude and age-adjusted odds ratios. Results By data download on 30.6.2012, 1,307 participants (including 1,012 HHT-subjects, 142 controls) completed the questionnaire. Ages (medians 55/53ys), gender (65/65% female) and general demographics were similar. The number of current/former smokers did not differ significantly between HHT and control groups (p = 0.38), but the HHT arm reported significantly greater pack year smoking histories than the controls (Mann Whitney p = 0.01). Combining data of participants and relatives resulted in a control-arm of 2,817 (52% female), and HHT-arm of 2,166 (58% female). Median ages were77ys [IQR 65–82] and 66ys [IQR 53–77] respectively. Rates of 15 cancers predominantly recognised as primary cancers in the control group generally matched the age standardised frequency of the general population. The ratio of observed/expected incidence was significantly higher for cancers at common sites of metastatic spread (lung, liver and brain). As expected cancer rates increased with age (p < 0.0001, all cancers). In both crude and age-adjusted regression, lung cancers were significantly less frequent in the HHT arm compared to controls (age-adjusted odds ratio 0.48 [0.30, 0.70], p = 0.0012). Conclusions Individuals with HHT may be protected against primary and/or metastatic lung cancer. This does not appear to be due to reduced smoking habit. References Bernabeu and Shovlin, Thomson Reuters Pharma (21 December 2011) [Online].
doi_str_mv 10.1136/thoraxjnl-2013-204457.159
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1781820808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4027177921</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2129-50b84534e53962e68e2d7f37e132fc952f4e4c14708c84f51d0b1511519a6d653</originalsourceid><addsrcrecordid>eNqVkMtu1DAUhiMEEkPhHYxYp9jxNUsYtVOkFroos2BjeZyTxEMSB9vTy44NO56SJ6lHqbpHsnxs6fvP0fmK4j3Bp4RQ8TH1Ppj7_TSUFSY0X4xxeUp4_aJYESZUSatavCxWGDNcCirF6-JNjHuMsSJEroq_1_W_33_OZtfA6PzgO2fNgOIh3MJDLl0HMUU0HKYOWTNZCMjlL8SIrB9HPyE3odkkB1PG7lzqUQ8BGpdMeEC9gdGH0JvcFSUYzNQ5sMlEZ47x2WQSJZ_fUwp-iG-LV60ZIrx7qifF9_Ozm_VFeflt82X96bLcVaSqS453inHKgNNaVCAUVI1sqQRCq9bWvGoZMEuYxMoq1nLS4B3hJJ_aiEZwelJ8WPrOwf865A313h_ClEdqIhVRFVZYZapeKBt8jAFaPQc35r00wfooXz_L10f5epGvs_ycLZesiwnun4Mm_NRCUsn11-1abzY3n7dX5z_0NvNs4Xfj_j_GPAJa8J6X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781820808</pqid></control><display><type>article</type><title>P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls</title><source>Alma/SFX Local Collection</source><creator>Hosman, AE ; Devlin, HL ; Silva, BM ; Elphick, AH ; Shovlin, CL</creator><creatorcontrib>Hosman, AE ; Devlin, HL ; Silva, BM ; Elphick, AH ; Shovlin, CL</creatorcontrib><description>Background Over 41,000 people are diagnosed with lung cancer annually in the UK with only 8% of men, and 9% of women surviving at least 5 years after diagnosis. Antibodies against the endothelial cell protein endoglin are proving promising in early clinical trials [1]. Many individuals with hereditary haemorrhagic telangiectasia (HHT) have inherited endoglin mutations. This autosomal dominant trait affects approximately 1 in 5,000 people, causing multi-systemic vascular lesions. We hypothesised that lung cancer rates may differ in individuals with HHT. Methods To provide sufficient power to compare lung cancer rates in HHT patients and controls, we developed a questionnaire capturing data on multiple relatives per respondent, powered to detect differences in lung cancer rates. Blinded to cancer responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subject, unknown, or control. Logistic and quadratic regression were used to calculate crude and age-adjusted odds ratios. Results By data download on 30.6.2012, 1,307 participants (including 1,012 HHT-subjects, 142 controls) completed the questionnaire. Ages (medians 55/53ys), gender (65/65% female) and general demographics were similar. The number of current/former smokers did not differ significantly between HHT and control groups (p = 0.38), but the HHT arm reported significantly greater pack year smoking histories than the controls (Mann Whitney p = 0.01). Combining data of participants and relatives resulted in a control-arm of 2,817 (52% female), and HHT-arm of 2,166 (58% female). Median ages were77ys [IQR 65–82] and 66ys [IQR 53–77] respectively. Rates of 15 cancers predominantly recognised as primary cancers in the control group generally matched the age standardised frequency of the general population. The ratio of observed/expected incidence was significantly higher for cancers at common sites of metastatic spread (lung, liver and brain). As expected cancer rates increased with age (p &lt; 0.0001, all cancers). In both crude and age-adjusted regression, lung cancers were significantly less frequent in the HHT arm compared to controls (age-adjusted odds ratio 0.48 [0.30, 0.70], p = 0.0012). Conclusions Individuals with HHT may be protected against primary and/or metastatic lung cancer. This does not appear to be due to reduced smoking habit. References Bernabeu and Shovlin, Thomson Reuters Pharma (21 December 2011) [Online].</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2013-204457.159</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Lung cancer</subject><ispartof>Thorax, 2013-12, Vol.68 (Suppl 3), p.A78-A79</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Hosman, AE</creatorcontrib><creatorcontrib>Devlin, HL</creatorcontrib><creatorcontrib>Silva, BM</creatorcontrib><creatorcontrib>Elphick, AH</creatorcontrib><creatorcontrib>Shovlin, CL</creatorcontrib><title>P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls</title><title>Thorax</title><addtitle>Thorax</addtitle><description>Background Over 41,000 people are diagnosed with lung cancer annually in the UK with only 8% of men, and 9% of women surviving at least 5 years after diagnosis. Antibodies against the endothelial cell protein endoglin are proving promising in early clinical trials [1]. Many individuals with hereditary haemorrhagic telangiectasia (HHT) have inherited endoglin mutations. This autosomal dominant trait affects approximately 1 in 5,000 people, causing multi-systemic vascular lesions. We hypothesised that lung cancer rates may differ in individuals with HHT. Methods To provide sufficient power to compare lung cancer rates in HHT patients and controls, we developed a questionnaire capturing data on multiple relatives per respondent, powered to detect differences in lung cancer rates. Blinded to cancer responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subject, unknown, or control. Logistic and quadratic regression were used to calculate crude and age-adjusted odds ratios. Results By data download on 30.6.2012, 1,307 participants (including 1,012 HHT-subjects, 142 controls) completed the questionnaire. Ages (medians 55/53ys), gender (65/65% female) and general demographics were similar. The number of current/former smokers did not differ significantly between HHT and control groups (p = 0.38), but the HHT arm reported significantly greater pack year smoking histories than the controls (Mann Whitney p = 0.01). Combining data of participants and relatives resulted in a control-arm of 2,817 (52% female), and HHT-arm of 2,166 (58% female). Median ages were77ys [IQR 65–82] and 66ys [IQR 53–77] respectively. Rates of 15 cancers predominantly recognised as primary cancers in the control group generally matched the age standardised frequency of the general population. The ratio of observed/expected incidence was significantly higher for cancers at common sites of metastatic spread (lung, liver and brain). As expected cancer rates increased with age (p &lt; 0.0001, all cancers). In both crude and age-adjusted regression, lung cancers were significantly less frequent in the HHT arm compared to controls (age-adjusted odds ratio 0.48 [0.30, 0.70], p = 0.0012). Conclusions Individuals with HHT may be protected against primary and/or metastatic lung cancer. This does not appear to be due to reduced smoking habit. References Bernabeu and Shovlin, Thomson Reuters Pharma (21 December 2011) [Online].</description><subject>Lung cancer</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqVkMtu1DAUhiMEEkPhHYxYp9jxNUsYtVOkFroos2BjeZyTxEMSB9vTy44NO56SJ6lHqbpHsnxs6fvP0fmK4j3Bp4RQ8TH1Ppj7_TSUFSY0X4xxeUp4_aJYESZUSatavCxWGDNcCirF6-JNjHuMsSJEroq_1_W_33_OZtfA6PzgO2fNgOIh3MJDLl0HMUU0HKYOWTNZCMjlL8SIrB9HPyE3odkkB1PG7lzqUQ8BGpdMeEC9gdGH0JvcFSUYzNQ5sMlEZ47x2WQSJZ_fUwp-iG-LV60ZIrx7qifF9_Ozm_VFeflt82X96bLcVaSqS453inHKgNNaVCAUVI1sqQRCq9bWvGoZMEuYxMoq1nLS4B3hJJ_aiEZwelJ8WPrOwf865A313h_ClEdqIhVRFVZYZapeKBt8jAFaPQc35r00wfooXz_L10f5epGvs_ycLZesiwnun4Mm_NRCUsn11-1abzY3n7dX5z_0NvNs4Xfj_j_GPAJa8J6X</recordid><startdate>201312</startdate><enddate>201312</enddate><creator>Hosman, AE</creator><creator>Devlin, HL</creator><creator>Silva, BM</creator><creator>Elphick, AH</creator><creator>Shovlin, CL</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201312</creationdate><title>P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls</title><author>Hosman, AE ; Devlin, HL ; Silva, BM ; Elphick, AH ; Shovlin, CL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2129-50b84534e53962e68e2d7f37e132fc952f4e4c14708c84f51d0b1511519a6d653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Lung cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosman, AE</creatorcontrib><creatorcontrib>Devlin, HL</creatorcontrib><creatorcontrib>Silva, BM</creatorcontrib><creatorcontrib>Elphick, AH</creatorcontrib><creatorcontrib>Shovlin, CL</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosman, AE</au><au>Devlin, HL</au><au>Silva, BM</au><au>Elphick, AH</au><au>Shovlin, CL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>2013-12</date><risdate>2013</risdate><volume>68</volume><issue>Suppl 3</issue><spage>A78</spage><epage>A79</epage><pages>A78-A79</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><notes>ark:/67375/NVC-GGTBVMFZ-V</notes><notes>ArticleID:thoraxjnl-2013-204457.159</notes><notes>local:thoraxjnl;68/Suppl_3/A78-b</notes><notes>istex:5671E5EA5876C5713F6DA8AEE42854B9BE7870CD</notes><notes>href:thoraxjnl-68-A78-2.pdf</notes><abstract>Background Over 41,000 people are diagnosed with lung cancer annually in the UK with only 8% of men, and 9% of women surviving at least 5 years after diagnosis. Antibodies against the endothelial cell protein endoglin are proving promising in early clinical trials [1]. Many individuals with hereditary haemorrhagic telangiectasia (HHT) have inherited endoglin mutations. This autosomal dominant trait affects approximately 1 in 5,000 people, causing multi-systemic vascular lesions. We hypothesised that lung cancer rates may differ in individuals with HHT. Methods To provide sufficient power to compare lung cancer rates in HHT patients and controls, we developed a questionnaire capturing data on multiple relatives per respondent, powered to detect differences in lung cancer rates. Blinded to cancer responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subject, unknown, or control. Logistic and quadratic regression were used to calculate crude and age-adjusted odds ratios. Results By data download on 30.6.2012, 1,307 participants (including 1,012 HHT-subjects, 142 controls) completed the questionnaire. Ages (medians 55/53ys), gender (65/65% female) and general demographics were similar. The number of current/former smokers did not differ significantly between HHT and control groups (p = 0.38), but the HHT arm reported significantly greater pack year smoking histories than the controls (Mann Whitney p = 0.01). Combining data of participants and relatives resulted in a control-arm of 2,817 (52% female), and HHT-arm of 2,166 (58% female). Median ages were77ys [IQR 65–82] and 66ys [IQR 53–77] respectively. Rates of 15 cancers predominantly recognised as primary cancers in the control group generally matched the age standardised frequency of the general population. The ratio of observed/expected incidence was significantly higher for cancers at common sites of metastatic spread (lung, liver and brain). As expected cancer rates increased with age (p &lt; 0.0001, all cancers). In both crude and age-adjusted regression, lung cancers were significantly less frequent in the HHT arm compared to controls (age-adjusted odds ratio 0.48 [0.30, 0.70], p = 0.0012). Conclusions Individuals with HHT may be protected against primary and/or metastatic lung cancer. This does not appear to be due to reduced smoking habit. References Bernabeu and Shovlin, Thomson Reuters Pharma (21 December 2011) [Online].</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><doi>10.1136/thoraxjnl-2013-204457.159</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0040-6376
ispartof Thorax, 2013-12, Vol.68 (Suppl 3), p.A78-A79
issn 0040-6376
1468-3296
language eng
recordid cdi_proquest_journals_1781820808
source Alma/SFX Local Collection
subjects Lung cancer
title P9 Epidemiological survey suggests lung cancer is less common in patients with hereditary haemorrhagic telangiectasia compared to controls
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T21%3A20%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P9%E2%80%85Epidemiological%20survey%20suggests%20lung%20cancer%20is%20less%20common%20in%20patients%20with%20hereditary%20haemorrhagic%20telangiectasia%20compared%20to%20controls&rft.jtitle=Thorax&rft.au=Hosman,%20AE&rft.date=2013-12&rft.volume=68&rft.issue=Suppl%203&rft.spage=A78&rft.epage=A79&rft.pages=A78-A79&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thoraxjnl-2013-204457.159&rft_dat=%3Cproquest_cross%3E4027177921%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2129-50b84534e53962e68e2d7f37e132fc952f4e4c14708c84f51d0b1511519a6d653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1781820808&rft_id=info:pmid/&rfr_iscdi=true